Pazufloxacin

Records for this ingredient, by country (identity only).

ATC J01MA · 2 markets · 112 records

Pazufloxacin 2 markets · 112 records Forms
Filters
MarketCN 107JP 5

CN 107 records · 12 shown of 14 Source 国家医保局 医保药品分类与代码数据库 · Data as of 2025-04-04

  • 300 mg per mL / per unit basis not statedinjection君普帕珠沙星尼赛信、派斯欣、米斯龙、菲迅奇、锋珠新、Manufacturer: 华北制药股份有限公司、Manufacturer: 大同五洲通制药有限责任公司、Manufacturer: 扬子江药业集团有限公司 +1
  • 100 mL per mL / per unit basis not statedinjection佳乐同欣帕珠沙星博信、尼赛信、恒沐、莱美净、齐若达、Manufacturer: 浙江莎普爱思药业股份有限公司、Manufacturer: 湖南正清制药集团股份有限公司、Manufacturer: 辰欣药业股份有限公司 +1
  • 500 mg/100 mLinjection亚征利帕珠沙星敏星、派抒可、齐若达、Manufacturer: 山东齐都药业有限公司、Manufacturer: 扬子江药业集团有限公司、Manufacturer: 陕西金裕制药股份有限公司 also in JP
  • 300 mg/100 mLinjection巴红帕珠沙星敏星、米斯龙、Manufacturer: 扬子江药业集团有限公司、Manufacturer: 湖北广济药业股份有限公司、Manufacturer: 陕西金裕制药股份有限公司 also in JP
  • 300 mg/10 mLinjection君普帕珠沙星威利仙、安替、旭原、法多琳、锋珠新、Manufacturer: 四川美大康佳乐药业有限公司
  • 500 mg per mL / per unit basis not statedinjection威利仙帕珠沙星Manufacturer: 华北制药股份有限公司、Manufacturer: 四川百利药业有限责任公司、Manufacturer: 江苏康缘药业股份有限公司
  • 500 mg/10 mLinjection法多琳帕珠沙星Manufacturer: 遂成药业股份有限公司
  • 300 mg/5 mLinjection加易尼帕珠沙星Manufacturer: 扬子江药业集团有限公司
  • 100 mg/2 mLinjection莱美净帕珠沙星Manufacturer: 成都利尔药业有限公司
  • 0.9 mg/0.3 mLliquidManufacturer: 浙江莎普爱思药业股份有限公司 ×9
  • 0.3 % per mL / per unit basis not statedliquidManufacturer: 浙江莎普爱思药业股份有限公司 ×9
  • 300 mg/2 mLinjection尼赛信帕珠沙星
Other strengths: 2 · 1 dosage forms Otras concentraciones: 2 · 1 formas farmacéuticas 其余规格 2 个 · 涉及 1 种剂型 其餘規格 2 個 · 涉及 1 種劑型 · 300 mg/20 mL

JP 5 records · 3 shown of 3 Source 厚生労働省 薬価基準収載品目リスト · Data as of 2026-11-01

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

Also called: 甲磺酸帕珠沙星 nickname

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.